Covidien (COV) Weakner on Generic Filing
Tweet Send to a FriendGet Alerts COV Hot Sheet
Up)
Trade COV Now!
Covidien plc (NYSE: COV) is seeing a little weakness early Wednesday after FDA data shows an unidentified generic challenger for PENNSAID (diclofenac sodium topical solution), an FDA approved topical non-steroidal anti-inflammatory drug for osteoarthritis of the knee.
Share of COV last traded at $56.79, down 0.7 percent.
Link
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Share of COV last traded at $56.79, down 0.7 percent.
Link
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Covidien and Mallinckrodt to Present at Deutsche Bank Conference
- Boston Scientific (BSX) Reports Positive Results from NG PROMUS, EVOLVE
- St. Jude Medical (STJ) Issues Encouraging Update for EnligHTN™ Multi-Electrode Renal Denervation System Following One Year
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
